Resolution of human immunodeficiency virus type 1 infection-related severe pulmonary hypertension in a very low-birth-weight infant.
Pulmonary arterial hypertension (PAH) affects approximately 0.5% of human immunodeficiency virus (HIV)-infected adults with poor prognosis. The effectiveness of highly active antiretroviral therapy for treatment of HIV-related PAH (HIV-PAH) remains controversial. Little is known about the incidence, clinical course, and therapy options for PAH in HIV-1-infected pediatric patients. Here, we report the case of a preterm infant with HIV-related life-threatening PAH, which resolved after initiation of highly active antiretroviral therapy.
Feiterna-Sperling
Cornelia
C
Department of Pediatric Pneumology, Charité, University Medicine Berlin, Berlin, Germany. cornelia.feiterna-sperling@charite.de
Hüseman
Dieter
D
Timme
Jens
J
Bührer
Christoph
C
Obladen
Michael
M
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D004452:Echocardiography; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000821:virology*; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D013902:Radiography, Thoracic
D019380:Anti-HIV Agents